Eli Lilly and Company (LLY)vsSanara Medtech Inc (SMTI)
LLY
Eli Lilly and Company
$1,131.42
-0.26%
HEALTHCARE · Cap: $948.95B
SMTI
Sanara Medtech Inc
$22.12
+5.48%
HEALTHCARE · Cap: $197.03M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 67120% more annual revenue ($72.25B vs $107.48M). LLY leads profitability with a 35.0% profit margin vs -31.2%. LLY trades at a lower P/E of 37.7x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SMTI
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+58.4%
Fair Value
$46.72
Current Price
$22.12
$24.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
18.6% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.9% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SMTI
The strongest argument for SMTI centers on Revenue Growth. Revenue growth of 18.6% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : SMTI
The primary concerns for SMTI are EPS Growth, Market Cap, Return on Equity. A P/E of 358.3x leaves little room for execution misses. Debt-to-equity of 6.88 is elevated, increasing financial risk.
Key Dynamics to Monitor
SMTI carries more volatility with a beta of 1.19 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 29/100), backed by strong 35.0% margins and 55.5% revenue growth. SMTI offers better value entry with a 58.4% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Sanara Medtech Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Sanara MedTech Inc. develops, markets and distributes skin and wound care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company is headquartered in Fort Worth, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?